In ophthalmological clinical trials, sociodemographic disparities still exist.

Published Date: 01 Mar 2023

Ophthalmological Clinical Trials Still Show Sociodemographic Disparities.

Read Full News

Latest News

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Glaucoma Coaches Boost Med Adherence, Study Finds

Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less distress related to their condition.

Common Glaucoma Med May Undermine Trabeculectomy Success

Topical brimonidine is linked to a significantly increased risk for trabeculectomy failure in patients with glaucoma due to elevated intraocular pressure.

Endophthalmitis a Risk for Years After Tube Shunt Surgery

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Todays Updates

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Todays Updates

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Latest News

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less distress related to their condition.

Topical brimonidine is linked to a significantly increased risk for trabeculectomy failure in patients with glaucoma due to elevated intraocular pressure.

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

News All Time

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Q3 2025 Recap: Ophthalmology News and Updates Ryan Livingston

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

Correlation Between Diabetes and Risk of Uveitis Confirmed in Recent Study Ryan Livingston

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

Recommended News For You

The diamonds that could find cancer

Two medications might work better for breast cancers that are resistant to one.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

Investigations may result in novel combination therapies for early-stage lung cancers.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

Surgeons are at higher risk of cancer, study suggests

Recommended Articles For You

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide 

Subchorionic Hematoma: Causes, Symptoms, and Treatment  

Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology 

IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High levels of traumatic stress found in caregivers of adult cancer patients

2.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

3.

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.

4.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

5.

In a recent study, Kencur ginger's anti-cancer properties were discovered.

1.

The Different Types of Cysts and Why They Occur: Insights from a Dermatologist 

2.

Understanding Dasatinib: A Promising Drug for Cancer Treatment 

3.

TAR-200 in Bladder Cancer: Precision Drug Delivery Driving Oncology Advances

4.

Case Study: The Role of Machine Learning in the Detection of Skin Cancer

5.

Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

3.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

5.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot